Olsalazine versus sulfasalazine in mild to moderate childhood ulcerative colitis: results of the Pediatric Gastroenterology Collaborative Research Group Clinical Trial.

Published

Journal Article

The safety and efficacy of olsalazine sodium was compared to sulfasalazine over 3 months in a multicenter, randomized, double-blind study of 56 children with mild to moderate ulcerative colitis. Twenty-eight children received 30 mg/kg/day of olsalazine (maximum, 2 g/day) and 28 received 60 mg/kg/day of sulfasalazine (maximum, 4 g/day). Side effects were frequent in both groups. Eleven of 28 patients (39%) on olsalazine reported headache, nausea, vomiting, rash, pruritus, increased diarrhea, and/or fever. Thirteen of 28 on sulfasalazine (46%) reported similar side effects and/or neutropenia, and four patients had the drug stopped because of an adverse reaction. After 3 months, 11 of 28 (39%) on olsalazine were asymptomatic or clinically improved, compared to 22 of 28 (79%) on sulfasalazine (p = 0.006). In addition, 10 of 28 patients on olsalazine versus one on sulfasalazine required prednisone because of lack of response or worsening of colitis (p = 0.005). The dose of olsalazine used in this clinical trial was thought to be equivalent to a standard dose of sulfasalazine, but fewer patients on olsalazine improved and a greater number had progression of symptoms when compared to sulfasalazine. Although side effects were slightly less frequent for olsalazine, the number of patients was too small to detect a clinically significant difference.

Full Text

Duke Authors

Cited Authors

  • Ferry, GD; Kirschner, BS; Grand, RJ; Issenman, RM; Griffiths, AM; Vanderhoof, JA; Fiedorek, SC; Winter, HS; Hassall, EG; Watkins, JB

Published Date

  • July 1993

Published In

Volume / Issue

  • 17 / 1

Start / End Page

  • 32 - 38

PubMed ID

  • 8102399

Pubmed Central ID

  • 8102399

International Standard Serial Number (ISSN)

  • 0277-2116

Digital Object Identifier (DOI)

  • 10.1097/00005176-199307000-00005

Language

  • eng

Conference Location

  • United States